6-12 months ago the large labs started buying bio data this spend is starting to ramp very aggressively. the labs are somewhat indiscriminate buyers with enormous budgets. the therapeutics market has long had buyers of data (large and small pharma) but they've historically been the exact opposite of huge-budget and indiscriminate this shift will distort the bio startup market in a bunch of ways. there will be a lot of short-termist behavior to try to get in front of this capital firehouse. but unlike the AI data labelers (mercor, et al) and the robotics labelers (mecka, et al), the bio startups serving up this data have a chance to emerge from this period with businesses that don't rely on selling data the best bio startups will use these sudden resources the labs are dumping on them to supercharge their novel assay and work towards independently powerful models and eventually directly produce therapies bio is the final frontier and its a very exciting time ahead for bio startups IMO